For nearly a decade, effective GLP-1 therapy for weight loss meant needles. That changed fast in 2026. With the FDA approval of Foundayo (orforglipron) in April and the January 2026 launch of the Wegovy pill, people seeking meaningful weight loss now have real oral options that don’t require an injection pen, a sharps container, or refrigeration. A third oral GLP-1, Rybelsus, has been available since 2019 but only for type 2 diabetes.
This guide breaks down all three FDA-approved oral GLP-1 medications available in the United States today, how they compare to each other and to injectable options, and how to think about whether a pill or an injection is the right fit for you. As your complete GLP-1 resource — injections and pills alike — WeightLossInjections.com built this guide to help you have an informed conversation with your healthcare provider.
Key Takeaways
- Three oral GLP-1s are FDA-approved in the U.S. as of mid-2026: Foundayo (orforglipron), the Wegovy pill (oral semaglutide 25 mg), and Rybelsus (oral semaglutide 3/7/14 mg).
- Only Foundayo and the Wegovy pill are approved specifically for weight loss; Rybelsus is approved only for type 2 diabetes, making weight-loss use off-label.
- Foundayo is the first small-molecule oral GLP-1, meaning it requires no fasting or water restrictions — a major adherence advantage.
- The Wegovy pill and Rybelsus are peptide-based and require strict morning dosing on an empty stomach with minimal water.
- Weight loss ranges from about 11-16.9% with Foundayo (ATTAIN-1) to ~16.6% with the Wegovy pill (OASIS 4), both below the roughly 22.5% seen with injectable Zepbound (tirzepatide).
- Cost varies widely — from $25/month with a Foundayo savings card to over $1,300/month list price for the Wegovy pill without insurance.
The Three FDA-Approved Oral GLP-1s
Foundayo (orforglipron) — the small-molecule newcomer
Foundayo, developed by Eli Lilly under the code name LY3502970, became the first oral small-molecule (non-peptide) GLP-1 receptor agonist approved for chronic weight management when the FDA cleared it on April 1, 2026. It was reviewed and approved in just 50 days under the FDA Commissioner’s National Priority Voucher (CNPV) program — the first drug ever approved through that pathway, according to Eli Lilly’s press release. Foundayo is approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It is not yet approved for type 2 diabetes, though Eli Lilly’s ACHIEVE program is expected to support a future application.
Because Foundayo is a small molecule rather than a fragile peptide, it survives the digestive tract without needing a special absorption enhancer. That means it can be taken once daily, at any time, with or without food or water — a first among GLP-1 therapies. For a full breakdown of how Foundayo works, its dosing, and where to fill a prescription, see our dedicated Foundayo guide.
Wegovy pill (oral semaglutide 25 mg) — the first oral GLP-1 approved for weight loss
Novo Nordisk’s oral semaglutide 25 mg tablet, marketed as the Wegovy pill, received FDA approval on December 22, 2025, and launched commercially in January 2026. It uses the same active ingredient as injectable Wegovy but at a much higher oral dose, made bioavailable through the SNAC (sodium N-the WeightLossInjections.com Staffcaprylate) absorption enhancer. The Wegovy pill is approved for chronic weight management in adults with obesity or overweight plus a comorbidity, and it also carries an indication for reducing major adverse cardiovascular events (MACE) in people with established cardiovascular disease.
Unlike Foundayo, the Wegovy pill must be taken first thing in the morning, on an empty stomach, with no more than 4 ounces of plain water, and you must wait at least 30 minutes before eating, drinking anything else, or taking other oral medications.
Rybelsus (oral semaglutide 3/7/14 mg) — the original oral GLP-1, for diabetes
Rybelsus was the first oral GLP-1 ever approved, clearing the FDA in September 2019. It remains approved only for type 2 diabetes management — not weight loss. Many clinicians prescribe it off-label for weight loss because it shares the same active ingredient as Ozempic and the Wegovy pill, but its maximum dose (14 mg) is much lower than the Wegovy pill’s 25 mg, and weight loss at that dose is modest — roughly 4-6 pounds as a secondary trial endpoint, according to the PIONEER program. For the full picture on why this matters, read our guide on Rybelsus for weight loss.
Quick Comparison Table
| Drug | Class | Label | Fasting Required? | Max Dose | Approx. Weight Loss |
|---|---|---|---|---|---|
| Foundayo (orforglipron) | Small-molecule oral | Weight loss | No | Per label | 11-16.9% (ATTAIN-1) |
| Wegovy pill | Oral peptide (semaglutide) | Weight loss + MACE reduction | Yes (strict) | 25 mg | ~16.6% (OASIS 4) |
| Rybelsus | Oral peptide (semaglutide) | Type 2 diabetes only | Yes (strict) | 14 mg | ~4-6 lbs (secondary endpoint) |
| Wegovy injection | Injectable peptide | Weight loss + MACE reduction | N/A | 2.4 mg/week | ~14.9% |
| Zepbound | Injectable dual GIP/GLP-1 | Weight loss + OSA | N/A | 15 mg/week | ~22.5% |
Weight loss figures reflect mean results from pivotal trials and vary by individual. Always discuss expected outcomes with your healthcare provider.
Our Top 3 · July 2026
The best GLP-1 providers right now
Independently reviewed. Ranked by price, medication access, provider quality, and patient outcomes.
Renew GLP
Personalized GLP-1, GIP plans: Semaglutide & Tirzepatide.
Medvi
No membership or hidden fees. Everything you need is included.
Trimi
US-licensed clinicians and shipped to your door, from $99/mo.
How Oral GLP-1s Work
All GLP-1 receptor agonists — pill or injection — mimic the hormone glucagon-like peptide-1, which slows gastric emptying, reduces appetite, and improves insulin response. The delivery mechanism is where oral and injectable options diverge:
- Peptide-based orals (Wegovy pill, Rybelsus): These use the same large peptide molecule found in injectables like Ozempic and Wegovy, stabilized with an absorption enhancer (SNAC) that helps the fragile peptide survive stomach acid. Because absorption is inefficient and food interferes with it, strict fasting rules apply.
- Small-molecule orals (Foundayo): Orforglipron is a fundamentally different type of molecule — non-peptide, more like a traditional small-molecule drug (think ibuprofen rather than insulin). It doesn’t need an absorption enhancer and isn’t degraded by stomach acid or affected by food the same way, which is why it comes with no fasting requirement.
The trade-off, based on trial data to date, is that small-molecule GLP-1 agonism tends to produce somewhat lower peak weight loss than the peptide-based options or dual-acting injectables like Zepbound or Mounjaro.
When Pills Make Sense vs. When Injections Make Sense
Consider an oral GLP-1 if:
- You have needle aversion or discomfort with self-injection
- You travel frequently and want to avoid refrigeration logistics (injectable pens generally require cold storage; oral tablets do not)
- You want the highest reachable adherence with the fewest routine burdens — particularly with Foundayo’s no-fasting flexibility
- You’re pursuing a modest, gradual weight-loss goal and prioritize simplicity
Consider an injectable if:
- You want the highest documented efficacy — injectable options like tirzepatide-based Zepbound and Mounjaro currently produce the largest average weight loss of any GLP-1 or dual-agonist class
- You’d rather manage medication weekly instead of daily
- Cost and insurance coverage favor an injectable in your specific plan (coverage varies significantly by drug and insurer)
- You’re also considering options like compounded semaglutide or newer agents such as retatrutide, which currently only exist as injectables
There’s no universally “better” option — the right choice depends on your health profile, goals, tolerance for fasting rules, and insurance coverage. A healthcare provider can help weigh efficacy against convenience for your situation.
Cost and Adherence at a Glance
Cost varies enormously by drug, insurance status, and pharmacy channel. Foundayo can be as low as $25/month with commercial insurance and a savings card, or $149-349/month self-pay, with a $50/month option through the Medicare GLP-1 Bridge program starting July 1, 2026. The Wegovy pill lists around $1,349/month before savings programs. Rybelsus lists near $1,000/month but often benefits from stronger insurance coverage since it’s an established diabetes drug. For the full cost breakdown across all three, see our detailed oral GLP-1 cost guide.
Adherence is more nuanced than “pills are easier.” Foundayo’s no-fasting design genuinely simplifies daily life, but the Wegovy pill and Rybelsus both require a fairly rigid morning routine — take on an empty stomach, minimal water, and a 30-minute wait — that some patients find just as demanding as a once-weekly injection.
FAQ
Is an oral GLP-1 as effective as an injectable for weight loss?
Not quite, based on current trial data. Foundayo showed 14.7-16.9% weight loss at 52 weeks in ATTAIN-1, and the Wegovy pill showed about 16.6% at 64 weeks in OASIS 4, compared to roughly 22.5% with injectable Zepbound. Injectables currently lead on peak efficacy, while orals lead on convenience.
Can I switch from an injectable GLP-1 to an oral one?
Switching between GLP-1 formulations is a medical decision that depends on your dose, response, and health history. Only a healthcare provider should guide a transition between an injectable like Ozempic or Wegovy and an oral option like Foundayo or the Wegovy pill.
Which oral GLP-1 has the fewest food and water restrictions?
Foundayo (orforglipron) is the only oral GLP-1 that can be taken with or without food or water, at any time of day. Both the Wegovy pill and Rybelsus require empty-stomach morning dosing with minimal water and a 30-minute wait before eating or drinking.
Is Rybelsus FDA-approved for weight loss?
No. Rybelsus is FDA-approved only for type 2 diabetes management. Any use for weight loss is considered off-label, though it is legal for a healthcare provider to prescribe it that way when clinically appropriate.
How much does an oral GLP-1 cost per month?
It depends heavily on the drug and your insurance. Foundayo can range from $25/month with insurance and a savings card up to $149-349/month self-pay. The Wegovy pill lists around $1,349/month, and Rybelsus lists near $1,000/month. See our full cost comparison for details.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Foundayo (orforglipron), Wegovy pill (oral semaglutide 25 mg), and Rybelsus (oral semaglutide 3/7/14 mg) are prescription medications with important safety information and contraindications. Discuss any medication decision with a qualified healthcare provider. Content published by WeightLossInjections.com, your complete resource for GLP-1 medications — injections and pills alike.
